Michael D. Kaufman

5.5k total citations
85 papers, 2.8k citations indexed

About

Michael D. Kaufman is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Michael D. Kaufman has authored 85 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 23 papers in Molecular Biology and 18 papers in Oncology. Recurrent topics in Michael D. Kaufman's work include Multiple Sclerosis Research Studies (22 papers), Polyomavirus and related diseases (6 papers) and Asymmetric Synthesis and Catalysis (6 papers). Michael D. Kaufman is often cited by papers focused on Multiple Sclerosis Research Studies (22 papers), Polyomavirus and related diseases (6 papers) and Asymmetric Synthesis and Catalysis (6 papers). Michael D. Kaufman collaborates with scholars based in United States, Canada and Germany. Michael D. Kaufman's co-authors include Paul A. Grieco, Joseph Norton, Amos B. Smith, Hirokazu Arimoto, Matthew J. LaMarche, Thomas J. Beauchamp, John Rose, Jacob Elkins, Gilmore O’Neill and Susan K. Johnson and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Michael D. Kaufman

82 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael D. Kaufman United States 27 1.0k 704 669 653 431 85 2.8k
Ying Yang China 41 432 0.4× 1.7k 2.4× 594 0.9× 2.2k 3.3× 502 1.2× 136 5.1k
Rainer Albert Switzerland 25 276 0.3× 705 1.0× 625 0.9× 2.2k 3.3× 473 1.1× 60 3.7k
Patrick J. Creaven United States 35 630 0.6× 2.1k 3.0× 226 0.3× 1.4k 2.1× 164 0.4× 127 3.9k
Sylvain Cottens Switzerland 16 286 0.3× 387 0.5× 309 0.5× 1.8k 2.8× 813 1.9× 26 3.5k
Yvette N. Lamb New Zealand 28 243 0.2× 483 0.7× 221 0.3× 954 1.5× 322 0.7× 63 2.8k
Bruce F. Kimler United States 37 662 0.7× 1.4k 2.0× 106 0.2× 1.4k 2.1× 291 0.7× 228 4.5k
John J. McGuire United States 36 151 0.2× 601 0.9× 1.1k 1.6× 1.9k 2.9× 225 0.5× 176 4.9k
Yoshitaka Yamamura Japan 47 698 0.7× 2.6k 3.7× 261 0.4× 1.7k 2.6× 274 0.6× 164 10.8k
Josephia R. Muindi United States 36 929 0.9× 652 0.9× 119 0.2× 1.8k 2.8× 168 0.4× 60 3.3k
Mauro Bologna Italy 36 160 0.2× 1.1k 1.5× 184 0.3× 1.7k 2.6× 210 0.5× 116 3.5k

Countries citing papers authored by Michael D. Kaufman

Since Specialization
Citations

This map shows the geographic impact of Michael D. Kaufman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Kaufman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Kaufman more than expected).

Fields of papers citing papers by Michael D. Kaufman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Kaufman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Kaufman. The network helps show where Michael D. Kaufman may publish in the future.

Co-authorship network of co-authors of Michael D. Kaufman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Kaufman. A scholar is included among the top collaborators of Michael D. Kaufman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Kaufman. Michael D. Kaufman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 74. 128928–128928. 19 indexed citations
2.
Smith, Bryan D., Michael D. Kaufman, Scott Wise, et al.. (2021). Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Molecular Cancer Therapeutics. 20(11). 2098–2109. 40 indexed citations
3.
Sakai, Tetsuro, Stephen Aniskevich, Daniela Damian, et al.. (2021). Adult liver transplant anesthesiology practice patterns and resource utilization in the United States: Survey results from the society for the advancement of transplant anesthesia. Clinical Transplantation. 36(1). e14504–e14504. 16 indexed citations
4.
Harney, Allison S., George S. Karagiannis, Jeanine Pignatelli, et al.. (2017). The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. Molecular Cancer Therapeutics. 16(11). 2486–2501. 105 indexed citations
5.
Kaufman, Michael D., et al.. (2016). Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis. Journal of Neuroimmunology. 300. 59–65. 11 indexed citations
6.
Kappos, Ludwig, Krzysztof Selmaj, Douglas L. Arnold, et al.. (2015). Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003). Neurology. 84(14_supplement). 3 indexed citations
7.
Kappos, Ludwig, Heinz Wiendl, Krzysztof Selmaj, et al.. (2015). Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine. 373(15). 1418–1428. 199 indexed citations
8.
Rose, John, Heinz Wiendl, Douglas L. Arnold, et al.. (2015). Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252). Neurology. 84(14_supplement). 2 indexed citations
9.
Fox, Robert J., Bruce Cree, J. de Sèze, et al.. (2014). MS disease activity in RESTORE. Neurology. 82(17). 1491–1498. 144 indexed citations
10.
11.
Cree, Bruce, J. de Sèze, Robert J. Fox, et al.. (2013). Natalizumab Effects during a 6-Month Dose Interruption: Relationship of Pharmacokinetic (PK), Pharmacodynamic (PD), and MRI Measurements (S41.003). Neurology. 80(7_supplement). 1 indexed citations
12.
Ahn, Yu Mi, Michael Clare, Carol L. Ensinger, et al.. (2010). Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20(19). 5793–5798. 26 indexed citations
13.
Singh, Rishi P., et al.. (2010). Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis. British Journal of Ophthalmology. 94(2). 170–173. 15 indexed citations
14.
Schumann, Roman, Stephanie B. Jones, Scott D. Kelley, et al.. (2009). Update on Best Practice Recommendations for Anesthetic Perioperative Care and Pain Management in Weight Loss Surgery, 2004–2007. Obesity. 17(5). 889–894. 49 indexed citations
15.
Barrett, Stephen D., Alexander J. Bridges, David T. Dudley, et al.. (2008). The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorganic & Medicinal Chemistry Letters. 18(24). 6501–6504. 222 indexed citations
16.
Johnson, Susan K., et al.. (2006). The Effect of Ginkgo Biloba on Functional Measures in Multiple Sclerosis: A Pilot Randomized Controlled Trial. EXPLORE. 2(1). 19–24. 46 indexed citations
17.
Kaufman, Michael D., Stephen D. Barrett, Cathlin Flamme, et al.. (2004). Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor.. Cancer Research. 64. 573–573. 1 indexed citations
18.
Kaufman, Michael D., et al.. (2003). Multiple Sclerosis. American Journal of Physical Medicine & Rehabilitation. 82(8). 582–590. 56 indexed citations
19.
Johnson, Susan K., et al.. (1999). A Controlled Investigation of Bodywork in Multiple Sclerosis. The Journal of Alternative and Complementary Medicine. 5(3). 237–243. 45 indexed citations
20.
Kaufman, Michael D.. (1998). Do Microbes with Peptides Mimicking Myelin Cause Multiple Sclerosis if the T Cell Response to their Unique Peptides is Limited?. Journal of Theoretical Biology. 193(4). 691–708. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ying Yang Breakdown of academic impact, for papers by Rainer Albert Breakdown of academic impact, for papers by Patrick J. Creaven Breakdown of academic impact, for papers by Sylvain Cottens Breakdown of academic impact, for papers by Yvette N. Lamb Breakdown of academic impact, for papers by Bruce F. Kimler Breakdown of academic impact, for papers by John J. McGuire Breakdown of academic impact, for papers by Yoshitaka Yamamura Breakdown of academic impact, for papers by Josephia R. Muindi Breakdown of academic impact, for papers by Mauro Bologna
Rankless by CCL
2026